Sara MillsSenior Principal & Head of Cell Therapy, CMC at Dark Horse ConsultingSpeaker
Profile
Sara came into industry over 14 years ago by way of UCSF where she was in the neurosurgery department studying glioblastoma, epigenetics and pluripotent stem cells. Sara joined Dark Horse Consulting Group (DHC) in 2016 and in her current roll enjoys leading a team of cell therapy and gene-modified cell therapy subject matter experts in supporting small, academic through large and late-stage programs developing CMC strategies to allow swift movement with minimal risks so as to maximize success in the long run. This work includes a minimum of at least 80 clients and 90 products in 9 different regulatory jurisdictions.
Agenda Sessions
Chairperson's Opening Remarks
, 8:55amView Session